Skin Symptoms

  • Frank Brennan
  • Mathew Dutton
  • Linda Magann
Living reference work entry


The skin is the largest organ of the body. In life-limiting illnesses, there are a number of important skin manifestations that may cause considerable suffering to patients and, indirectly, to their family and carers. They include pruritus, pathological sweating, skin failure, and malignant cutaneous wounds. This chapter will review the pathophysiological mechanisms, epidemiology, assessment, and management of these manifestations. Each section will be accompanied by a set of evidence-based management recommendations for clinicians.


  1. Alexander S. Malignant fungating wounds: epidemiology, aetiology, presentation and assessment. J Wound Care. 2009;18(7):273–80.PubMedGoogle Scholar
  2. Aperis G, Paliouras C, Zervos A, et al. The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. J Renal Care. 2010;36(4):180–5.Google Scholar
  3. Aramwit P, Keongamaroon O, Siritientong T, et al. Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study. BMC Nephrol. 2012;13:119.PubMedPubMedCentralGoogle Scholar
  4. Australian Wound Management Association. Pan Pacific clinical practice guideline for the prevention and management of pressure injury. West Leederville: Cambridge Media Osborne Park; 2012.Google Scholar
  5. Berg CL, Gollan JL. Primary biliary cirrhosis: new therapeutic directions. Scand J Gastroenterol Suppl. 1992;192:43–9.PubMedGoogle Scholar
  6. Bergasa NV. Pruritus of cholestasis. In: Carstens E, Akiyama T, editors. Itch – mechanisms and treatment. Boca Raton: CRC Press; 2014. p. 65.Google Scholar
  7. Bergasa NV, Talbot TL, Alling DW, et al. A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology. 1992;102(2):544–9.PubMedGoogle Scholar
  8. Bergasa NV, Liau S, Homel P, et al. Hepatic Met-enkephalin immunoreactivity is enhanced in primary biliary cirrhosis. Liver. 2002;22(2):107–13.PubMedGoogle Scholar
  9. Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006;44:1317–23.PubMedGoogle Scholar
  10. Beuers U, Kremer AE, Bolier R, et al. Pruritus in cholestasis – facts and fiction. Hepatology. 2014;60(1):399–407.PubMedGoogle Scholar
  11. Booken N, Heck M, Nicolay JP. Oral aprepitant in the therapy if refractory pruritus in erythrodermic cutaneous T-cell lymphoma. Brit J Dermatol. 2011;164:665–83.Google Scholar
  12. Breneman DL, Cardone JS, Blumsack RF, et al. Topical capsaicin for treatment of haemodialysis-related pruritus. J Am Acad Dermatol. 1992;26:91–4.PubMedGoogle Scholar
  13. Brennan F. The pathophysiology of pruritus – a review for clinicians. Prog Pall Care. 2016;24(3):133–46.Google Scholar
  14. Brown G. Long term outcomes of full thickness pressure areas: healing and mortality. Ostomy Wound Manage. 2003;9(10):42–50.Google Scholar
  15. Calder K, Bruera E. Thalidomide for night sweats in patients with advanced cancer. Palliat Med. 2000;14:77–8.PubMedGoogle Scholar
  16. Chen YC, Chiu W-T, Wu M-S. Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. Am J Kidney Dis. 2006;48:69–76.PubMedGoogle Scholar
  17. Combs SA, Teixeira JP, Germain MJ. Pruritus in kidney disease. Semin Nephrol. 2015;35(40):383–91.PubMedPubMedCentralGoogle Scholar
  18. Datna DV, Sherlock S. Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis. Gastroenterology. 1966;50(3):323–32.Google Scholar
  19. Dawn AG, Yosipovitch G. Butorphanol for the treatment of intractable pruritus. J Am Acad Dermatol. 2006;54:527–31.PubMedGoogle Scholar
  20. Decock S, Roelandts R, Steenbergen WV, et al. Cholestasis-induced pruritus treated with ultraviolet-B phototherapy: an observational case series. J Hepatol. 2012;57(3):637–41.PubMedGoogle Scholar
  21. Demierre M-F, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma. J Am Acad Dermatol. 2006;55(3):543–4.PubMedGoogle Scholar
  22. Dowsett C. Malignant fungating wounds: assessment and management. Br J Community Nurs. 2002;7(8):394–400.PubMedGoogle Scholar
  23. Duque MI, Yosipovitch G, Fleisher AB, et al. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol. 2005;52:519–21.PubMedGoogle Scholar
  24. Duval A, Dubertret L. Aprepitant as an antipruritic agent ? N Engl J Med. 2009;361(14):1415–6.PubMedGoogle Scholar
  25. Ghent CN, Carruthers SG. Treatment of pruritus in primary biliary cirrhosis with rifampacin. Results of a double-blind, crossover, randomized trial. Gastroenterology. 1988;94:488–93.PubMedGoogle Scholar
  26. Gilchrest BA, Rowe JW, Brown RS, et al. Relief of uremic pruritus with ultraviolet phototherapy. N Engl J Med. 1977;297:136–8.PubMedGoogle Scholar
  27. Gilchrest BA, Rowe JW, Brown RS, et al. Ultraviolet phototherapy of uremic pruritus. Ann Intern Med. 1979;91:17–21.PubMedGoogle Scholar
  28. Gingold AR, Bergasa NV. The cannabinoid agonist WIN 55, 212-2 increases nocioception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci. 2003;73(2):2741–7.PubMedGoogle Scholar
  29. Goode PS, Allman RM. The prevention and management of pressure ulcers. Med Clin North Am. 1989;73(6):1511–24.PubMedGoogle Scholar
  30. Gonclaves F. Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin’s disease. Am J Hosp Palliat Care. 2010;27(7):486–7.Google Scholar
  31. Grocott PR. Palliative management of Fungating malignant wounds. Eur J Cancer. 1995;31:S308.Google Scholar
  32. Haffenreffer S. De pruritu, Nosodochium in Quo Cutis. In: Eique Adhaerentium Partium, Affectus Omnes, Singulari Methodo, Et Cognoscendi Et Curandi Fidelissime Traduntur. Ulm: Kuhnen Balthasar; 1660. p. 98–102.Google Scholar
  33. Heathcote EJ. Is rifampicin a safe and effective treatment for pruritus caused by chronic cholestasis? Nat Clin Pract Gastroenterol Heapatol. 2007;494:200–1.Google Scholar
  34. Hobbs RN. Walk with me – physicians’ and patients’ stories and their role in palliative care education. J Palliat Care. 1993;9(2):41–6.PubMedGoogle Scholar
  35. Irvine B. Developments in palliative nursing in and out of the hospital settings. Br J Nurs. 2016;2(4):218–24.Google Scholar
  36. Karadag E, Kilic SP, Karatay G, et al. Effect of baby oil on pruritus, sleep quality, and quality of life in hemodialysis patients: pretest-post-test model with control groups. Jpn J Nurs Sci. 2014;11:180–9.PubMedGoogle Scholar
  37. Kilic A, Gul U, Soylu S. Skin findings in internal malignant diseases. Int J Dermatol. 2007;46:1055–60.PubMedGoogle Scholar
  38. Kim KH, Lee MS, Choi SM. Acupuncture for treating uremic pruritus in patients with end-stage renal disease; a systematic review. J Pain Symptom Manag. 2010;40:117–25.Google Scholar
  39. Ko MJ, Yang JY, HY W, et al. Narrowband ultraviolet B phototherapy for patients with refractory uraemic pruritus: a randomized controlled trial. Brit J Dermatol. 2011;165:633–9.Google Scholar
  40. Kremer AE, Beuers U, Oude-Elferink RP, et al. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163–82.PubMedGoogle Scholar
  41. Kremer AE, Martens JJ, Kulik W, et al. Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology. 2010;139:1008–18.PubMedGoogle Scholar
  42. Kremer AE, van Dijk R, Leckie P, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology. 2012;56:1391–400.PubMedGoogle Scholar
  43. Kremer AE, Bolier R, van Dijk R, et al. Advances in pathogenesis and management of pruritus in cholestasis. Dig Dis. 2014;32:637–45.PubMedGoogle Scholar
  44. Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo controlled study. Nephrol Dial Transplant. 2010;25(4):1251–7.PubMedGoogle Scholar
  45. Kumagai H, Ebata T, Takamori K, et al. Efficacy and safety of a novel k-agonist for managing intractable pruritus in dialysis patients. Am J Nephrol. 2012;36:175–83.PubMedGoogle Scholar
  46. Kuypers DR, Claes K, Evenepoel P, et al. A prospective proof of concept study of the efficacy of tacrolimus ointment on uremic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant. 2004;19:1895–901.PubMedGoogle Scholar
  47. Langemo DK, Brown G. Skin fails too: acute, chronic and end-stage skin failure. Adv Skin Wound Care. 2006;19(4):206–11.PubMedGoogle Scholar
  48. La Puma J. The ethics of pressure ulcers. Adv Skin Wound Care. 1991;4(2):43–5.Google Scholar
  49. Lau T, Leung S, Lau W. Gabapentin for uremic pruritus in hemodialysis patients: a qualitative systematic review. Can J Kidney Health Dis. 2016;3:1–14.Google Scholar
  50. Legroux-Crespel E, Cledes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology. 2004;208:326–30.PubMedGoogle Scholar
  51. Lin TC, Lai YH, Guo SE, et al. Baby oil therapy for uremic pruritus in hemodialysis patients. J Clin Nurs. 2012;21:139–48.PubMedGoogle Scholar
  52. Lo S, Hu W, Hayter M, Chang S, Hsu M, Wu L. Experiences of living with a malignant fungating wound: a qualitative study. J Clin Nurs. 2008;17(20):2699–708.PubMedGoogle Scholar
  53. Maida V. Nabilone for the treatment of paraneoplastic night sweats: a report of four cases. J Palliat Med. 2008;11(6):929–34.PubMedGoogle Scholar
  54. Maida V, Ennis M, Kuziemsky C, Trozzolo L. Symptoms associated with malignant wounds: a prospective case series. J Pain Symptom Manag. 2009;37(2):206–11.Google Scholar
  55. Makhlough A, Ala S, Haj-Heydari Z, et al. Topical capsaicin therapy for uremic pruritus in patients on hemodialysis. Iran J Kidney Dis. 2010;4:137–40.PubMedGoogle Scholar
  56. Mathur VS, Lindberg J, Germain M, et al. A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5:1410–9.PubMedPubMedCentralGoogle Scholar
  57. Mayo MM, Handem I, Saldana S, et al. Sertraline as a first line treatment for cholestatic pruritus. Hepatology. 2007;45:666–74.PubMedGoogle Scholar
  58. McCormick PA, Scott F, Epstein O, et al. Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. J Hepatol. 1994;21:496–9.PubMedGoogle Scholar
  59. McMurray V. Managing patients with fungating malignant wounds. Nurs Times. 2003;99(13):55–7.PubMedGoogle Scholar
  60. Mettang T. Pruritus in kidney disease. In: Carstens E, Akiyama T, editors. Itch – mechanisms and treatment. Boca Raton: CRC Press; 2014.Google Scholar
  61. Morton CA, Lafferty M, Lau C, et al. Pruritus and skin hydration during dialysis. Nephrol Dial Transplant. 1996;11:2031–6.PubMedGoogle Scholar
  62. Murphy M, Reaich D, Pai P, et al. A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Brit J Dermatol. 2003;148(2):314–7.Google Scholar
  63. Murtagh FEM, Addington-Hall JM, Edmonds PM, et al. Symptoms in advanced renal disease: a cross-sectional survey of symptom prevalence in stage 5 chronic kidney diseases managed without dialysis. J Palliat Med. 2007;10(6):1266–76.PubMedGoogle Scholar
  64. Nasrollahi A, Miladipour A, Ghanei E, et al. Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iran J Kidney Dis. 2007;1(2):73–7.PubMedGoogle Scholar
  65. National Pressure Ulcer Advisory Panel. NPUAP Pressure Injury Stages. United States of America: National Pressure Ulcer Advisory Panel; 2016 (Cited 2016 October 10). Available from:
  66. Naylor W. Assessment and management of pain in fungating wounds. Br J Nurs. 2001;10(Sup5):S33–56.PubMedGoogle Scholar
  67. Neff GW, O’Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol. 2002;97(8):2117–9.PubMedGoogle Scholar
  68. Nieto-Posadas A, Picazo-Juaraez G, Llorente I, et al. Lysophosphatidic acid directly activates TRPV1 through a C-binding site. Nat Chem Biol. 2012;8:78–85.Google Scholar
  69. Noble H, Meyer J, Bridge J, et al. Exploring symptoms in patients managed without dialysis: a qualitative research study. J Ren Care. 2010;36(1):9–15.PubMedGoogle Scholar
  70. Papiou ADP, Emerson NM, Patel TS, et al. Voxel-based morphometry and arterial spin labelling fMRI reveal neuropathic and neuroplastic features of brain processing of itch in end-stage renal disease. J Neurophysiol. 2014;112:1729–38.Google Scholar
  71. Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis. 2007;50:11–20.PubMedGoogle Scholar
  72. Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol. 2000;11:514–9.PubMedGoogle Scholar
  73. Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uremic pruritus. Lancet. 1996;348:1552–4.PubMedGoogle Scholar
  74. Pisoni RL, Wikstrom B, Elder SJ, et al. Pruritus in haemodialysis patients: international results from Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006;21:3495–505.PubMedGoogle Scholar
  75. Probst S, Arber A, Faithful S. Malignant fungating wounds – the meaning of living in an unbounded body. Eur J Oncol Nurs. 2013:38–45.Google Scholar
  76. Rayner H, Baharani J, Smith S, et al. Uraemic pruritus: relief of itching by gabapentin and pregabalin. Nephron Clin Pract. 2012;122:75–9.PubMedGoogle Scholar
  77. Razeghi E, Ejkandari D, Ganji M, et al. Gabapentin and uremic pruritus in hemodialysis patients. Ren Fail. 2009;31(2):85–90.PubMedGoogle Scholar
  78. Rowe B, Yosipovitch G. Paraneoplastic itch management. In: Szepietowski JC, Weisshaar E, editors. Itch – Management in Clinical Practice. Basel: Karger; 2016. p. 149–54.Google Scholar
  79. Rubenstein M, Duvic M. Cutaneous manifestations of Hodgkin’s Disease. Int J Dermatol. 2006;45:252–6.Google Scholar
  80. Schank JE. Kennedy terminal ulcer: the “ah-ha!” moment. Ostomy Wound Manage. 2009;55(9):40–44.PubMedGoogle Scholar
  81. Seaman S. Management of malignant fungating wounds in advanced cancer. Semin Oncol Nurs. 2006;22(3):185–93.PubMedGoogle Scholar
  82. Shakiba M, Sanadgol H, Azmoude HR et al. Effect of sertraline on uremic pruritus improvement in ESRD patients. Int J Nephrol. 2012:363901; 1–5.Google Scholar
  83. Shavit L, Grenader T, Lifschitz M, et al. Use of pregabalin in the management of chronic uremic pruritus. J Pain Symptom Manag. 2013;45(4):776–81.Google Scholar
  84. Sibbald RG, Krasner DL, Lutz J. SCALE: skin changes at life’s end final consensus statement. Adv Skin Wound Care. 2009;23(5):225–36.Google Scholar
  85. Silva SRB, Viana PCF, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron. 1994;67:270–3.PubMedGoogle Scholar
  86. Smith CJ, Johnson JM. Responses to hyperthermia. Optimizing heat dissipation by convection and evaporation: neural control of skin blood flow and sweating in humans. Auton Neurosci. 2016;196:25–36.PubMedGoogle Scholar
  87. Solak Y, Biyik Z, Atalay H, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology. 2012;17:71–717.Google Scholar
  88. Stander S, Luger TA. NK-I antagonists and itch. In: Cowan A, Yosipovitch A, editors. Pharmacology of itch. Heidelberg: Springer; 2015.Google Scholar
  89. Swain MG. Pruritus and lethargy in the primary biliary cirrhosis patient. In: Neuberger J, editor. Primary biliary cirrhosis. Eastbourne: West End Studios; 1999. p. 75–81.Google Scholar
  90. Ta Y, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatol Treat. 2009;20:76–81.Google Scholar
  91. Tan JK, Haberman HF, Coldman AJ. Identifying effective treatments for uremic pruritus. J Am Acad Dermatol. 1991;25(5 Pt 1):811–8.PubMedGoogle Scholar
  92. Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampicin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol. 2007;102(7):1528–36.PubMedGoogle Scholar
  93. Tarng DC, Cho YL, Liu HN, et al. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron. 1996;72:617–22.PubMedGoogle Scholar
  94. Terg R, Coronel E, Sorda J, et al. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol. 2002;37(60):717–22.PubMedGoogle Scholar
  95. Thornton JR, Losowsky MS. Opioid peptides and primary biliary cirrhosis. Br Med J. 1988;297(6662):1501–4.Google Scholar
  96. To T, Clark K, Lam L, et al. The role of ondansetron in the management of cholestatic or uremic pruritus – a systematic review. J Pain Symptom Manag. 2012;44:725–30.Google Scholar
  97. Trivedi M, Bergasa NV. Serum concentrations of substance P in cholestasis. Ann Hepatol. 2010;99(2):177–80.Google Scholar
  98. Twycross R, Wilcock A, Howard P, editors. Palliative Care Formulary. 5th ed. Nottingham: Palliative Care; 2014.Google Scholar
  99. Villafranca JJA, Siles M, Casanova M, et al. Paraneoplastic pruritus presenting with Hodgkin’s lymphoma; a case report. J Med Case Reports. 2014;8:300.Google Scholar
  100. Villamil AG, Bandi JC, Galdame O, et al. Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. Am J Med. 2005;118(10):1160–3.PubMedGoogle Scholar
  101. Waran E. Doctor, I am sweating on just one side of my body: unilateral hyperhidrosis associated with mesothelioma. Clin Case Rep. 2016;4(5):533–4.PubMedPubMedCentralGoogle Scholar
  102. Weisshaar E, Dunkler N, Rohl FW, et al. Antipruritic effects of two different 5-HT3 receptor antagonists and an antihistamine in haemodialysis patients. Exp Dermatol. 2004;24:298–304.Google Scholar
  103. Weisshaar E, Szepietowski JC, Drashow U, et al. European guideline on chronic pruritus. Acta Derm Venereol. 2012;92:563–81.PubMedGoogle Scholar
  104. Weisshaar E, Weiss M, Mettang T, Yosipovitch G, Zylicz Z. Paraneoplastic itch: an expert position statement from the Special Interest Group (SIG) of the International Forum on the Study of Itch (IFSI). Acta Derm Venerol. 2015;95:261–5.PubMedGoogle Scholar
  105. Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus : multicentre, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol. 2005;16:3742–7.PubMedGoogle Scholar
  106. Wilson V. Assessment and management of fungating wounds: a review. Br J Community Nurs. 2005;10(Sup1):S28–34.PubMedGoogle Scholar
  107. Witkowski JA, Parrish LC. The decubitus ulcer. Skin failure and destructive behaviour. Int J Dermatol. 2000;39(12):894–6.PubMedGoogle Scholar
  108. Wolfhagen FHJ, Sternieri E, Hop WCJ, et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 1997;113(4):1264–9.PubMedGoogle Scholar
  109. Worley CA. The permissible pressure ulcer. Dermatol Nurs. 2007;19:384–5.PubMedGoogle Scholar
  110. Yoshimoto-Furuie K, Yoshimoto K, Tanaka T, et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms on hemodialysis patients. Nephron. 1999;81:151–9.PubMedGoogle Scholar
  111. Yosipovitch G, Bernhard JD. Clinical practice – chronic pruritus. New Engl J Med. 2013;368:1625–34.PubMedGoogle Scholar
  112. Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatol Treat. 2009;20(2):76–81.Google Scholar
  113. Yue J, Jiao S, Xiao Y, et al. Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. Int Urol Nephrol. 2015;47(1):161–7.PubMedGoogle Scholar
  114. Zylicz Z, Krajnik M. Flushing and sweating in an advanced breast cancer patient relieved by Olanzapine. J Pain Sympt Manage. 2003;25(6):494–5.Google Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Frank Brennan
    • 1
  • Mathew Dutton
    • 2
  • Linda Magann
    • 3
  1. 1.Palliative Care PhysicianSt George and Calvary HospitalsSydneyAustralia
  2. 2.Wound Management Clinical Nurse ConsultantSt George HospitalSydneyAustralia
  3. 3.Palliative Care Clinical Nurse ConsultantSt George HospitalSydneyAustralia

Personalised recommendations